Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer

NCT00031941 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00031941
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00031941 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multidose Phase I Study of Oral CC5013, a Thalidomide Derivative, in Patients With Refractory Metastatic Cancer
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2002
Completion date
April 30, 2009
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, small intestine cancer, unspecified adult solid tumor, protocol specific